Protocol Ledger

NCT05619926 · Phase II · COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Interventional Phase II clinical trial protocol NCT05619926 sponsored by Staidson (Beijing) Biopharmaceuticals Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-09 Enrollment: 32 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05619926
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)32 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05619926
Protocol FieldVerified Registry Value
NCT IdentifierNCT05619926
Consolidated Lead SponsorStaidson (Beijing) Biopharmaceuticals Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment32 participants (ACTUAL)
Registered Start Date2023-01-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI